Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the <scp>ToPiND</scp> randomized controlled trial-Reference-Cited by-同舟云学术

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial

Published:2022-05-16 Issue:9 Volume:6 Page:2273-2285
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Yoneda Masato¹^ORCID,Kobayashi Takashi¹^ORCID,Honda Yasushi¹,Ogawa Yuji²,Kessoku Takaomi¹,Imajo Kento³,Nogami Asako¹,Taguri Masataka⁴,Kirikoshi Hiroyuki⁵,Saito Satoru¹,Nakajima Atsushi¹^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology Yokohama City University Graduate School of Medicine Yokohama Japan

2. Gastroenterology Division National Hospital Organization Yokohama Medical Center Yokohama Japan

3. Department of Gastroenterology Shin‐yurigaoka General Hospital Kawasaki Japan

4. Department of Data Science Yokohama City University School of Data Science Yokohama Japan

5. Laboratory of Physiology Yokohama City University Hospital Yokohama Japan

Funder

Kowa Company

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1993

Reference49 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis

3. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040

4. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

5. Inherited Forms of Primary Hyperaldosteronism: New Genes, New Phenotypes and Proposition of A New Classification

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors;Advances in Medical Sciences;2024-09

2. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

3. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease;Hepatology;2024-05-08

4. A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis;RSC Medicinal Chemistry;2024

5. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial;The Lancet Gastroenterology & Hepatology;2023-12